Eli Lilly to Acquire Merida for $2.875 Billion to Secure MER511
Lilly Bets Big on Early-Stage Autoimmune Platform
Eli Lilly and Company (LLY) has finalized a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash. The total amount includes upfront payments and conditional milestones tied to development, regulatory, and commercialization achievements. The transaction reflects Lilly's strategy to reallocate cash generated from its GLP-1 business into its immunology pipeline to diversify growth drivers. Given that MER511 is still in Phase 1 clinical trials, Lilly is assigning high strategic value not only to the individual candidate but also to the antibody-engineering platform applicable to future indications.
MER511 Targets Disease-Causing Autoantibodies and Their Source
The investigational candidate MER511 is a precision biologic designed to selectively eliminate pathogenic autoantibodies that activate the thyroid-stimulating hormone receptor (TSHR) and the B-cell source responsible for producing these antibodies. It aims to directly reduce the upstream cause of Graves' disease and thyroid eye disease (TED) while preserving normal immunoglobulin and immune function. The Phase 1 NEXUS trial (NCT07305818), which began in December 2025 and targets 100 adult participants, is evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of single and repeated dose-escalation intravenous and subcutaneous administrations. Lilly reported that initial data showed a strong reduction in pathogenic thyroid-stimulating antibodies and a favorable early safety profile.
Competitive Landscape with Existing Therapies
Standard treatment for Graves' disease includes antithyroid drugs such as methimazole and propylthiouracil, radioactive iodine, and thyroidectomy, but none of these therapies precisely eliminate the disease-causing antibodies. For TED, Amgen (AMGN)'s Tepezza (teprotumumab-trbw, an IGF-1R inhibiting antibody) received FDA approval on January 21, 2020, and Viridian Therapeutics (VRDN)'s Lumvoa (veligrotug-vvze, an IGF-1R inhibiting antibody) was approved by the FDA on June 26, 2026, for TED treatment regardless of activity or disease duration. A direct competitor, Biohaven (BHVN)'s IgG1·2·4 degrader BHV-1300, entered Phase 3 trials for Graves' disease in June 2026. For MER511 to differentiate itself in later-stage trials, it must demonstrate superior preservation of normal immunity.
Market Potential and Development Risks
The global market for Graves' disease is estimated at $4.8 billion in 2025, while the TED market in the U.S., EU major countries, and Japan is valued at $2.4 billion. MER511 has the potential to expand beyond thyroid hormone regulation into TED and other autoantibody-mediated diseases, offering platform value beyond a single indication. However, Phase 1 trials do not confirm efficacy, and the primary completion date for the NEXUS trial is set for July 24, 2028. With Biohaven already in Phase 3 trials, Lilly's capital, clinical development, and commercialization capabilities will be key factors in narrowing the development speed gap.
The $2.875 billion acquisition price shows that Lilly is assigning strategic premium not only to the Phase 1 asset MER511 but also to the entire platform capable of precisely eliminating pathogenic autoantibodies and their B-cell sources. In the $4.8 billion global market for Graves' disease and the $2.4 billion TED market in the seven major countries, antithyroid drugs, radioactive iodine, surgery, and approved IGF-1R antibodies such as Tepezza and Lumvoa currently set the competitive benchmark. Biohaven's (BHVN) BHV-1300 has already entered Phase 3 trials, making the clinical speed and normal immunity preservation differentiation of MER511 key factors in short-term value assessment. In the medium to long term, if early safety and antibody reduction signals translate into clinical remission and discontinuation of antithyroid drugs, Lilly could expand both its immunology revenue base and competition in the autoantibody degrader acquisition space.